Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 65.3%

Neg 65.3% Neu 0% Pos 0%

Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.